Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

MLA

Humberto Caldera, et al. “Evaluation of Safety and Pharmacokinetics of Administering Intravenous Busulfan in a Twice-Daily or Daily Schedule to Patients with Advanced Hematologic Malignant Disease Undergoing Stem Cell Transplantation.” Biology of Blood and Marrow Transplantation, vol. 8, no. 9, Sept. 2002, pp. 486–92. EBSCOhost, https://doi.org/10.1053/bbmt.2002.v8.pm12374453.

APA

Humberto Caldera, Federico Albrecht, Hugo F. Fernandez, Shari Lennon, Hai T Tran, & Mark Goodman. (2002). Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biology of Blood and Marrow Transplantation, 8(9), 486–492. https://doi.org/10.1053/bbmt.2002.v8.pm12374453

Chicago

Humberto Caldera, Federico Albrecht, Hugo F. Fernandez, Shari Lennon, Hai T Tran, and Mark Goodman. 2002. “Evaluation of Safety and Pharmacokinetics of Administering Intravenous Busulfan in a Twice-Daily or Daily Schedule to Patients with Advanced Hematologic Malignant Disease Undergoing Stem Cell Transplantation.” Biology of Blood and Marrow Transplantation 8 (9): 486–92. doi:10.1053/bbmt.2002.v8.pm12374453.